DIVISLAB - Divi's Laboratories

Divi's Laboratories

DIVISLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Ramesh BV Nimmagadda · MD: Murali K Divi · Listing date: March 12, 2003 · Employees: 16818 · Hyderabad · http://www.divislabs.com

Stock Price vs Company Growth

1.2%

4.5%

6.2%

7.8%

4.7%

12.0%

10y

19.8%

all

22.3%

🤔 How to analyze this graph?

Last Traded Price

₹ 6,073 1.2%

5,956

6,904

Company Overview

Sales

10,029 Cr

Growth: 13.5%

Profit after Tax

2,485 Cr

Growth: 7.8%

Large Cap

1,61,208 Cr

P/E: 64.9x

Industry P/E: 30.2x

Fundamentals

Sales (Cr)	₹ 10,029
Growth	13.5%
EBITDA	32.4%
P/S	16.1x
Dividend	0.6%
P/E	64.9x
Book Value	₹ 610
PEG Ratio	4.7x
ROE	16.1%
P/B	9.8x

Shareholding Pattern

Institutions

Sbi Mutual Fund

4.49 %

Qualified Institutional Buyer

3.57 %

Axis Mutual Fund Trustee Ltd

3.37 %

Government Pension Fund Global

1.29 %

Life Insurance Corporation Of India

1.15 %

Promoters

Nilima Prasad Divi

20.34 %

Divi Satchandra Kiran

20.34 %

Divi Swarna Latha

5.27 %

Divi'S Biotech Private Limited

3.01 %

Murali Krishna Prasad Divi

2.85 %

Others

Increase Decrease No change

Company Profile Detailed

The company is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generics, the Company, through its custom synthesis, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.

Belongs to (51 Indices) view more

Investors (135)

credit.s...

vijaya.l...

y.vamsi....

Followers (42)

deepak

jayapras...

nitin2